
  
    
      
        Background_NNP
        Dystrophin_NNP and_CC its_PRP$ associated_VBN proteins_NNS are_VBP thought_VBN to_TO be_VB
        involved_VBN in_IN the_DT anchoring_VBG of_IN the_DT muscle_NN cell_NN membrane_NN to_TO
        the_DT extracellular_NN matrix_NN [_NN 1_CD ]_NN ,_, and_CC the_DT absence_NN of_IN many_JJ of_IN
        these_DT proteins_NNS can_MD lead_VB to_TO the_DT phenotype_NN of_IN muscular_JJ
        dystrophy_NN [_NN 2_CD ]_NN ._. The_DT dystrophin-associated_JJ protein_NN complex_JJ
        (_( DAPC_NNP )_) consists_VBZ of_IN several_JJ subgroups_NNS of_IN protein_NN complexes_NNS ,_,
        each_DT associated_VBN either_CC directly_RB or_CC indirectly_RB with_IN
        dystrophin_NN ._. The_DT sarcoglycans_NNS are_VBP four_CD transmembrane_NN
        proteins_NNS [_NN 3_CD ]_NN that_WDT are_VBP organized_VBN by_IN a_DT fifth_JJ protein_NN called_VBD
        sarcospan_NN [_NN 4_CD ]_NN ._. This_DT complex_NN is_VBZ thought_VBN to_TO be_VB involved_VBN in_IN
        signalling_VBG at_IN the_DT cell_NN membrane_NN [_NN 5_CD ]_NN ._. A_DT second_JJ subcomplex_NN ,_,
        known_VBN as_IN the_DT dystroglycan_NN complex_JJ [_NN 6_CD ]_NN ,_, interacts_NNS directly_RB
        with_IN dystrophin_NN in_IN the_DT cytoplasm_NN and_CC laminin_NN in_IN the_DT
        extracellular_NN matrix_NN ,_, thus_RB providing_VBG a_DT structural_JJ link_NN
        between_IN the_DT inside_JJ and_CC the_DT outside_JJ of_IN the_DT cell_NN ._. A_DT third_JJ
        subcomplex_NN involves_VBZ the_DT dystrobrevins_NNS [_NN 7_CD ,_, 8_CD ]_NN and_CC
        syntrophins_NNS [_NN 9_CD ]_NN which_WDT form_VBP a_DT complex_NN at_IN the_DT C-_NNP terminal_NN
        region_NN of_IN dystrophin_NN [_NN 10_CD ,_, 11_CD ,_, 12_CD ]_NN and_CC have_VBP an_DT as_RB yet_RB
        unidentified_JJ function_NN ._.
        Desmuslin_NNP (_( DMN_NNP )_) was_VBD recently_RB identified_VBN as_IN an_DT
        α-dystrobrevin-interacting_JJ protein_NN via_IN the_DT yeast_NN two-hybrid_JJ
        method_NN [_NN 13_CD ]_NN ._. Both_DT desmuslin_NN mRNA_NN and_CC protein_NN are_VBP expressed_VBN
        primarily_RB in_IN cardiac_JJ and_CC skeletal_NN muscle_NN and_CC the_DT gene_NN
        encodes_NNS a_DT novel_NN intermediate_JJ filament_NN (_( IF_IN )_) protein_NN of_IN 1253_CD
        amino_JJ acids_NNS ._. Electron_NNP microscopic_JJ analysis_NN shows_VBZ that_IN
        desmuslin_NN colocalizes_NNS with_IN desmin_NN ,_, another_DT muscle_NN IF_IN
        protein_NN ._. Co-immunopreciptation_NNP experiments_NNS revealed_VBD that_IN
        the_DT desmuslin_NN and_CC α-dystrobrevin_JJ interaction_NN involves_VBZ the_DT
        region_NN of_IN protein_NN encoded_JJ by_IN exons_NNS 8_CD -_: 16_CD of_IN α-dystrobrevin_JJ
        and_CC domains_NNS 1_CD A_DT through_IN 2_CD A_DT of_IN the_DT desmuslin_NN rod_NN domain_NN ._.
        Desmuslin_NNP is_VBZ hypothesized_VBN to_TO function_VB as_IN a_DT mechanical_JJ
        support_NN to_TO the_DT muscle_NN myofibers_NNS by_IN making_VBG a_DT previously_RB
        unrecognized_JJ linkage_NN between_IN the_DT extracellular_NN matrix_NN via_IN
        the_DT DAPC_NNP and_CC the_DT Z-_NNP discs_NNS through_IN desmin_NN and_CC plectin_NN [_NN
        14_CD ]_NN ._.
        As_IN several_JJ IF_IN proteins_NNS ,_, including_VBG desmin_NN ,_, have_VBP been_VBN
        implicated_VBN in_IN human_JJ genetic_JJ disorders_NNS such_JJ as_IN dominant_JJ and_CC
        recessive_JJ congenital_NN and_CC adult_NN onset_NN myopathies_NNS [_NN 15_CD ,_, 16_CD ,_,
        17_CD ,_, 18_CD ]_NN ,_, desmuslin_NN becomes_VBZ a_DT candidate_NN to_TO be_VB involved_VBN in_IN
        myopathies_NNS as_RB well_RB ._. Supporting_VBG this_DT is_VBZ the_DT exclusive_JJ
        expression_NN of_IN 
        DMN_NNP in_IN skeletal_NN and_CC cardiac_JJ muscle_NN ._.
        The_DT 
        DMN_NNP gene_NN was_VBD analyzed_VBN for_IN mutations_NNS
        in_IN 71_CD patients_NNS with_IN various_JJ forms_NNS of_IN muscular_JJ dystrophy_NN and_CC
        myopathy_NN ._. In_IN addition_NN to_TO 9_CD single-nucleotide_JJ polymorphisms_NNS
        (_( SNPs_NNP )_) that_WDT do_VBP not_RB change_VB the_DT protein_NN sequence_NN ,_, we_PRP
        identified_VBD 12_CD SNPs_NNP that_WDT do_VBP alter_VB the_DT residue_NN they_PRP encode_NN ._.
        Although_IN examination_NN of_IN controls_NNS has_VBZ shown_VBN that_DT none_NN of_IN
        them_PRP is_VBZ likely_JJ to_TO cause_VB the_DT phenotype_NN ,_, our_PRP$ results_NNS are_VBP
        useful_JJ for_IN future_JJ disequilibrium_NN studies_NNS of_IN this_DT region_NN of_IN
        chromosome_NN 15_CD q_NN 26_CD ._. 3_LS and_CC for_IN mutation_NN analysis_NN and_CC
        association_NN studies_NNS in_IN other_JJ genetic_JJ disorders_NNS ._.
      
      
        Results_NNS and_CC Discussion_NNP
        Using_VBG the_DT 
        DMN_NNP cDNA_NN sequence_NN (_( AF_NNP 359284_CD )_) as_IN a_DT
        query_NN to_TO blast_VB the_DT public_JJ human_JJ genome_NN database_NN ,_, we_PRP found_VBD a_DT
        genomic_JJ clone_NN (_( AC_NNP 018999_CD )_) that_WDT included_VBD the_DT entire_JJ desmuslin_NN
        coding_VBG sequence_NN ._. The_DT alignment_NN identified_VBD 5_CD exons_NNS which_WDT are_VBP
        schematically_RB indicated_VBN in_IN Figure_NN 1_CD ._. Eleven_CD sets_NNS of_IN primer_NN
        pairs_NNS were_VBD developed_VBN to_TO amplify_VB the_DT 5_CD exons_NNS and_CC the_DT
        flanking_VBG intron_NN sequences_NNS (_( Table_NNP 1_LS )_) ._. The_DT primers_NNS were_VBD
        designed_VBN to_TO amplify_VB overlapping_VBG segments_NNS of_IN the_DT desmuslin_NN
        coding_VBG sequence_NN as_IN indicated_VBN in_IN Figure_NN 1_CD ._.
        Desmin_NNP ,_, a_DT desmuslin-interacting_JJ protein_NN ,_, has_VBZ been_VBN
        implicated_VBN in_IN hereditary_JJ distal_NN myopathies_NNS implying_VBG that_DT
        desmuslin_NN itself_PRP may_MD also_RB be_VB involved_VBN in_IN myopathies_NNS of_IN
        unknown_JJ etiology_NN ._. DNA_NN samples_NNS isolated_VBN from_IN 71_CD dystrophic_JJ
        and_CC myopathic_JJ patients_NNS (_( as_IN described_VBN in_IN Table_NNP 2_LS )_) were_VBD
        analyzed_VBN by_IN direct_JJ sequencing_VBG to_TO determine_VB whether_IN the_DT
        phenotype_NN was_VBD the_DT result_NN of_IN a_DT desmuslin_NN mutation_NN ._. All_DT
        observed_VBD variants_NNS were_VBD subsequently_RB tested_VBN in_IN ≤_NN 156_CD control_NN
        individuals_NNS ._. These_DT analyses_NNS revealed_VBD 10_CD common_JJ and_CC 2_CD rare_JJ
        SNPs_NNP [_NN 19_CD ,_, 20_CD ]_NN that_WDT alter_VBP an_DT amino_JJ acid_NN codon_NN ;_: 7_CD result_NN in_IN
        non-conservative_JJ amino_JJ acids_NNS changes_NNS (_( Table_NNP 3_LS )_) ._.
        None_NN of_IN the_DT SNPs_NNP seem_VBP associated_VBN with_IN the_DT patient_NN
        phenotypes_NNS as_IN each_DT was_VBD also_RB found_VBN in_IN the_DT control_NN
        population_NN ._. Nine_CD silent_JJ SNPs_NNP ,_, which_WDT did_VBD not_RB alter_VB an_DT amino_JJ
        acid_NN ,_, were_VBD also_RB identified_VBN in_IN the_DT patient_NN population_NN ;_:
        several_JJ of_IN these_DT SNPs_NNP showed_VBD a_DT high_JJ degree_NN of_IN
        heterozygosity_NN ._. Most_JJS were_VBD tested_VBN for_IN and_CC detected_VBD in_IN the_DT
        control_NN population_NN ,_, thus_RB making_VBG desmuslin_NN an_DT unlikely_JJ
        candidate_NN to_TO be_VB involved_VBN in_IN these_DT myopathies_NNS ,_, but_CC this_DT
        first_JJ pass_NN can_MD be_VB followed_VBN by_IN others_NNS in_IN a_DT larger_JJR set_JJ of_IN
        patient_NN samples_NNS ._.
        Interestingly_RB ,_, SNP_NNP 3_CD ,_, a_DT C_NNP 598_CD T_NN substitution_NN resulting_VBG in_IN
        a_DT premature_JJ stop_NN codon_NN in_IN exon_NN 1_CD ,_, was_VBD detected_VBN in_IN a_DT single_JJ
        Nemaline_NNP myopathy_NN patient_NN ._. Neither_DT the_DT proband_NN 's_POS mother_NN nor_CC
        any_DT of_IN the_DT other_JJ patients_NNS was_VBD found_VBN to_TO carry_VB this_DT mutation_NN
        (_( Figure_NN 2_CD A_DT )_) ._. The_DT C_NNP 598_CD T_NN mutation_NN removed_VBD a_DT Pvu_NNP II_NNP site_NN ,_, thus_RB
        permitting_VBG detection_NN of_IN the_DT alteration_NN by_IN restriction_NN
        digest_VB analysis_NN of_IN a_DT PCR_NNP product_NN generated_VBN from_IN genomic_JJ
        DNA_NNP ._. The_DT assay_NN is_VBZ outlined_VBN schematically_RB in_IN Figure_NN 2_CD Band_NNP
        documented_VBN in_IN Figure_NN 2_CD C_NNP ._. Using_VBG this_DT Pvu_NNP II_NNP assay_NN ,_, the_DT C_NNP 598_CD T_NN
        change_NN was_VBD detected_VBN in_IN the_DT unaffected_JJ father_NN of_IN the_DT
        patient_NN ,_, making_VBG it_PRP unlikely_JJ that_DT heterozygosity_NN for_IN the_DT
        C_NNP 598_CD T_NN change_NN is_VBZ the_DT causative_JJ mutation_NN in_IN the_DT myopathic_JJ
        proband_NN ._.
        The_DT removal_NN of_IN the_DT Pvu_NNP II_NNP site_NN allowed_VBD rapid_JJ screening_NN
        of_IN additional_JJ patients_NNS and_CC control_NN samples_NNS by_IN DNA_NNP
        amplification_NN of_IN the_DT region_NN and_CC subsequent_JJ digestion_NN of_IN the_DT
        PCR_NNP product_NN with_IN Pvu_NNP II_NNP ._. One_CD of_IN 312_CD control_NN chromosomes_NNS was_VBD
        found_VBN to_TO have_VB lost_VBN the_DT Pvu_NNP II_NNP site_NN ,_, and_CC the_DT heterozygous_JJ
        presence_NN of_IN the_DT C_NNP 598_CD T_NN mutation_NN was_VBD confirmed_VBN by_IN DNA_NNP
        sequencing_VBG of_IN the_DT PCR_NNP product_NN ._. Thus_RB it_PRP is_VBZ likely_JJ that_IN the_DT
        C_NNP 598_CD T_NN mutation_NN is_VBZ not_RB responsible_JJ for_IN the_DT myopathic_JJ
        phenotype_NN of_IN the_DT proband_NN ._. This_DT is_VBZ a_DT surprising_JJ result_NN
        considering_VBG that_IN a_DT single_JJ copy_NN of_IN this_DT stop_NN codon_NN is_VBZ
        present_JJ in_IN 0_CD ._. 44_CD %_NN (_( 2_CD /_NN 454_CD )_) of_IN the_DT population_NN and_CC 0_CD ._. 002_CD %_NN of_IN
        the_DT population_NN is_VBZ predicted_VBN to_TO carry_VB this_DT nonsense_NN mutation_NN
        in_IN a_DT homozygous_JJ state_NN ._. The_DT phenotype_NN of_IN the_DT latter_JJ
        individuals_NNS is_VBZ not_RB known_VBN ._.
        There_EX is_VBZ the_DT possibility_NN that_IN either_DT the_DT heterozygous_JJ
        C_NNP 598_CD T_NN 
        DMN_NNP mutation_NN combined_VBN with_IN another_DT
        mutation_NN in_IN a_DT different_JJ gene_NN or_CC the_DT C_NNP 598_CD T_NN in_IN a_DT homozygous_JJ
        state_NN causes_NNS muscular_JJ dystrophy_NN or_CC myopathy_NN of_IN unknown_JJ
        genetic_JJ pathogenesis_NNS ._. The_DT C_NNP 598_CD T_NN 
        DMN_NNP mutation_NN is_VBZ a_DT good_JJ candidate_NN to_TO
        be_VB a_DT modifier_NN for_IN muscular_JJ and_CC /_NN or_CC cardiac_JJ phenotypes_NNS ,_,
        considering_VBG :_: (_( i_NNP )_) the_DT frequency_NN of_IN the_DT mutation_NN in_IN the_DT
        normal_JJ population_NN in_IN the_DT heterozygous_JJ as_IN well_RB as_IN homozygous_JJ
        state_NN ;_: and_CC (_( ii_NN )_) the_DT key_JJ role_NN of_IN desmuslin_NN in_IN connecting_VBG the_DT
        Z-_NNP discs_NNS to_TO the_DT extracellular_NN matrix_NN ._. The_DT desmuslin_NN SNPs_NNP
        should_MD be_VB examined_VBN in_IN a_DT larger_JJR set_JJ of_IN myopathy_NN and_CC muscular_JJ
        dystrophy_NN patients_NNS to_TO test_VB this_DT hypothesis_NNS ._. More_RBR
        specifically_RB ,_, it_PRP should_MD be_VB determined_VBN whether_IN there_EX is_VBZ a_DT
        statistically_RB significant_JJ difference_NN in_IN the_DT frequency_NN of_IN
        individual_JJ or_CC clustered_VBN SNP_NNP haplotypes_NNS between_IN the_DT patient_NN
        and_CC the_DT control_NN populations_NNS ._.
        The_DT desmuslin_NN coding_VBG sequence_NN is_VBZ highly_RB polymorphic_JJ with_IN
        9_CD SNPs_NNP that_WDT do_VBP not_RB alter_VB an_DT amino_JJ acid_NN and_CC 12_CD that_DT do_VBP ._. Ten_CD
        of_IN these_DT variations_NNS have_VBP minor_JJ allele_NN frequencies_NNS that_WDT are_VBP
        represented_VBN in_IN over_IN 10_CD %_NN of_IN the_DT chromosomes_NNS sampled_VBN ._. These_DT
        10_CD are_VBP spaced_JJ within_IN a_DT genomic_JJ interval_NN of_IN ≤_NN 28_CD kilobases_NNS ,_,
        or_CC approximately_RB 1_CD per_IN 2800_CD bases_NNS ._. These_DT highly_RB informative_JJ
        markers_NNS are_VBP thus_RB very_RB useful_JJ for_IN genetic_JJ analysis_NN ._. The_DT
        presence_NN of_IN so_RB many_JJ SNPs_NNP within_IN the_DT coding_VBG sequence_NN of_IN a_DT
        protein_NN is_VBZ somewhat_RB unexpected_JJ and_CC is_VBZ much_RB greater_JJR than_IN
        that_DT documented_VBN for_IN other_JJ genes_NNS ._. This_DT degree_NN of_IN variability_NN
        may_MD reflect_VB a_DT redundancy_NN of_IN desmuslin_NN at_IN the_DT Z-_NNP line_NN where_WRB
        other_JJ IF_IN proteins_NNS with_IN potentially_RB overlapping_VBG functions_NNS
        are_VBP located_VBN [_NN 21_CD ]_NN ._.
      
      
        Conclusions_NNP
        The_DT characterization_NN of_IN the_DT individual_JJ components_NNS that_WDT
        form_NN protein_NN complexes_NNS in_IN skeletal_NN muscle_NN and_CC heart_NN ,_,
        especially_RB information_NN concerning_VBG genotype-phenotype_JJ
        correlations_NNS ,_, will_MD increase_VB our_PRP$ understanding_NN of_IN the_DT
        pathophysiology_NN of_IN human_JJ muscle_NN diseases_NNS ._. We_PRP encourage_VBP
        other_JJ groups_NNS to_TO test_VB for_IN the_DT presence_NN of_IN the_DT C_NNP 598_CD T_NN 
        DMN_NNP mutation_NN in_IN their_PRP$ human_JJ patient_NN
        samples_NNS affected_VBN by_IN muscular_JJ and_CC cardiac_JJ diseases_NNS ._. The_DT
        generation_NN of_IN desmuslin_NN null_NN animal_NN models_NNS will_MD also_RB
        contribute_VB to_TO the_DT understanding_NN of_IN the_DT role_NN of_IN this_DT protein_NN
        in_IN muscle_NN and_CC cardiac_JJ disease_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        Blood_NNP samples_NNS were_VBD obtained_VBN from_IN patients_NNS and_CC control_NN
        subjects_NNS under_IN IRB-approved_NNP informed_VBD consent_NN ._. The_DT genomic_JJ
        DNA_NNP extracted_VBD from_IN these_DT blood_NN samples_NNS was_VBD used_VBN as_IN the_DT
        template_NN for_IN the_DT PCR_NNP assay_NN ._. Using_VBG an_DT Advantage-_NNP GC_NNP cDNA_NN PCR_NNP
        polymerase_NN (_( Clontech_NNP )_) and_CC 
        Pfu_NNP DNA_NNP polymerase_NN (_( Stratagene_NNP )_) ,_, PCR_NNP
        was_VBD carried_VBN out_IN with_IN primers_NNS specific_JJ to_TO the_DT exon_NN and_CC /_NN or_CC
        intron_NN of_IN 
        DMN_NNP sequence_NN (_( Table_NNP 1_LS )_) under_IN the_DT
        following_JJ conditions_NNS :_: 94_CD °_NN C_NNP for_IN 1_CD min_NN followed_VBN by_IN 35_CD cycles_NNS
        of_IN 94_CD °_NN C_NNP for_IN 1_CD min_NN ,_, 57_CD -_: 59_CD °_NN C_NNP for_IN 1_CD min_NN ,_, 72_CD °_NN C_NNP for_IN 3_CD min_NN and_CC a_DT
        final_JJ extension_NN time_NN of_IN 10_CD min_NN at_IN 72_CD °_NN C_NNP ._. The_DT amplification_NN
        products_NNS were_VBD purified_JJ using_VBG the_DT QIAGEN_NNP PCR_NNP purification_NN
        kit_NN and_CC analyzed_VBD on_IN either_DT an_DT ABI_NNP 373_CD or_CC 377_CD automated_VBN
        sequencer_NN with_IN fluorescent_NN dye_NN terminator_NN chemistry_NN
        (_( Applied_NNP Biosystems_NNP )_) ._.
        The_DT PCR_NNP products_NNS were_VBD also_RB digested_VBN with_IN Pvu_NNP II_NNP and_CC Msp_NNP
        I_PRP in_IN order_NN to_TO screen_VB for_IN the_DT C_NNP 598_CD T_NN and_CC C_NNP 2836_CD T_NN SNPs_NNP ,_,
        respectively_RB ._.
      
      
        Abbreviations_NNP
        DAPC_NNP :_: Dystrophin-associated_NNP protein_NN complex_JJ ;_: DMN_NNP :_:
        Desmuslin_NNP ,_, SNP_NNP :_: Single-nucleotide_NNP polymorphism_NN ;_: IF_IN :_:
        Intermediate_NNP filament_NN
      
    
  
